Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Past Highlights
Results:
1 -10 of 41
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
1.
Liver Safety Under Upfront Arimidex vs Tamoxifen
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase IV
Treatment
Active
Not specified
Pharmaceutical / Industry
D5392L00023
NCT00537771
2.
Second-Line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic ER Positive Breast Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Active
not specified
Other
N07MAN
Eudract 2007-007030-20, NCT00684216
Last Modified:
8/9/2007
 
First Published:
10/1/2002
3.
Phase III Randomized Study of Fluorouracil, Epirubicin, and Cyclophosphamide Versus Docetaxel, Epirubicin, and Cyclophosphamide in Women With Primary Breast Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 to 70
Other
LMU-ADEBAR
EU-20221, NCT00047099
Last Modified:
1/14/2009
 
First Published:
7/26/2003
4.
Phase III Randomized Study of Ovarian Function Suppression in Combination With Tamoxifen Versus Ovarian Function Suppression in Combination With Exemestane Versus Tamoxifen Alone in Premenopausal Women With Endocrine-Responsive Breast Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
Premenopausal
NCI
IBCSG-2402
BIG-2-02, CALGB-IBCSG-2402, CAN-NCIC-IBCSG-2402, NCCTG-IBCSG-2402, NSABP-IBCSG-2402, SWOG-IBCSG-2402, NABCI-IBCSG-2402, UCLA-0403024-01, EU-20334, IBCSG-24-02, NCT00066690, EUDRACT-2004-000166-13
Last Modified:
1/14/2009
 
First Published:
7/26/2003
5.
Phase III Randomized Study of Triptorelin and Exemestane Versus Triptorelin and Tamoxifen in Premenopausal Women With Endocrine-Responsive Breast Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
Premenopausal
NCI
IBCSG-25-02
BIG-3-02, NABCI-IBCSG-25-02, EU-20347, NCT00066703, EUDRACT-2004-000168-28
Last Modified:
4/29/2008
 
First Published:
10/25/2003
6.
Phase III Randomized Study of Adjuvant Tamoxifen Versus Anastrozole in Postmenopausal Women With Ductal Carcinoma In Situ
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
40 to 70
Other
CRUK-IBIS-II-DCIS
EU-20226, BIG-5-02, NCT00072462, IBCSG-31-03-DCIS, ISRCTN31488319
7.
Luteal v. Follicular Phase Surgical Oophorectomy & Tamoxifen in Premenopausal Women With Metastatic Hormone Receptor + Br. CA
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 and over
Other
OSU-0476
NCT00293540
Last Modified:
1/14/2009
 
First Published:
3/24/2006
8.
Phase III Randomized Study of Adjuvant Combination Chemotherapy and Hormonal Therapy Versus Adjuvant Hormonal Therapy Alone in Women With Previously Resected Axillary Node-Negative Breast Cancer With Various Levels of Risk for Recurrence (TAILORx Trial)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 to 75
NCI
ECOG-PACCT-1
SWOG-ECOG-PACCT-1, CALGB-ECOG-PACCT-1, NCCTG-ECOG-PACCT-1, NSABP-ECOG-PACCT-1, ACOSOG-ECOG-PACCT-1, CAN-NCIC-MAC12, PACCT-1, NCT00310180, TAILORx
9.
Different Durations of Adjuvant Anastrozole Therapy After 2 to 3 Years Tamoxifen Therapy in Breast Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 and over
Pharmaceutical / Industry
D5392NL0003
EUDRAct No: 2005-006167-31, NCT00301457
Last Modified:
6/18/2008
 
First Published:
2/5/2007
10.
Phase III Randomized Study of 70-Gene Signature Versus Clinical Assessment in Selecting Women With Node-Negative Breast Cancer for Adjuvant Chemotherapy
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 to 70
Other, Pharmaceutical / Industry
EORTC-10041
EUDRACT-2005-002625-31, BIG-3-04, NOVARTIS-EORTC-10041, ROCHE-EORTC-10041, SANOFI-AVENTIS-EORTC-10041, NCT00433589
Select All on One Page
1
2
3
4
Next >
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute